The ASITI-201 study

This study is examining the safety, tolerability and characteristics of a new drug called ASITI-201. This drug has the potential to stop or slow down the immune system’s attack of beta cells seen in type 1 diabetes.  

The trial aims to find out: 

• if ASITI-201 is safe
• if ASITI-201 helps stop the immune system from attacking insulin-producing cells in the pancreas
• what is the best dose to use. 

Study activities will be undertaken at the Princess Alexandra Hospital, Brisbane and participants need to attend in person.

Funding is available for participants in Queensland to travel to recruitment centres and clinic visits. 

Want to know more?  

Email: fi.thomasresearch@uq.edu.au